NASDAQ:INBX

Inhibrx Stock Insider Trading

Healthcare > Biotechnology

Buy INBX

*Your capital is at risk

$92.91

-0.390 (-0.418%)

At Close: Jun 23, 2026

Inhibrx Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -50.39. In total, the insiders bought 1.51M and sold 34.21M INBX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-50.39
● Buy	1.51M shares
● Sell	34.21M shares
41% Buy Activity Strong Negative Correlation
Buy Signal Low Confidence Jun 03, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -50.39. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Forsyth Douglas Director	Director	15 000 Value: $345.5K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Forsyth Douglas Director	Director	15 000 Value: $188.6K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Deck Kelly Chief Financial Officer	C-Suite Officer	14 583 Value: $490.4K
May 30, 2024 Sell	Common Stock D-Return	Eckelman Brendan P. Chief Scientific Officer	Officer	160 000 Value: $4.80M
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Forsyth Douglas Director	Director	15 000 Value: $188.6K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Deck Kelly Chief Financial Officer	C-Suite Officer	14 583 Value: $490.4K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Deck Kelly Chief Financial Officer	C-Suite Officer	21 250 Value: $495.1K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Forsyth Douglas Director	Director	15 000 Value: $345.5K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Forsyth Douglas Director	Director	17 259 Value: $181.6K
May 30, 2024 Sell	Common Stock D-Return	Forsyth Douglas Director	Director	598 257 Value: $17.9M
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Kayyem Jon Faiz Director	Director	15 000 Value: $371.7K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Forsyth Douglas Director	Director	15 000 Value: $371.7K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Eckelman Brendan P. Chief Scientific Officer	Officer	26 667 Value: $621.3K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Eckelman Brendan P. Chief Scientific Officer	Officer	6 667 Value: $224.2K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Deck Kelly Chief Financial Officer	C-Suite Officer	9 167 Value: $313.1K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Deck Kelly Chief Financial Officer	C-Suite Officer	21 250 Value: $495.1K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Manhard Kimberly Director	Director	15 000 Value: $371.7K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Manhard Kimberly Director	Director	15 000 Value: $188.6K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Manhard Kimberly Director	Director	15 000 Value: $345.5K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Manhard Kimberly Director	Director	3 500 Value: $61.0K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Vuori Kristiina Md Director	Director	15 000 Value: $188.6K
May 30, 2024 Sell	Stock Option (right to buy) D-Return	Vuori Kristiina Md Director	Director	15 000 Value: $345.5K
May 29, 2024 Sell	Common Stock, par value $0.0001 per share J-Other	Inhibrx, Inc. 10 Percent Owner	10% Owner	13 316 140 Value: $0
May 29, 2024 Sell	Common Stock, par value $0.0001 per share J-Other	Inhibrx, Inc. 10 Percent Owner	10% Owner	13 316 140 Value: $0
May 28, 2024 Sell	Common Stock S-Sale	Eckelman Brendan P. Chief Scientific Officer	Officer	300 000 Value: $10.3M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INHIBRX INC

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonis...

Read Full Profile Here